LDLRAD3 Inhibitors

LDLRAD3 inhibitors are a class of compounds that interact with the lipid metabolism pathways, particularly those involved in the regulation and clearance of low-density lipoprotein (LDL) cholesterol. These inhibitors do not target LDLRAD3 directly but can perturb its activity through modulation of cholesterol homeostasis and LDL receptor dynamics. Compounds such as statins (including simvastatin, atorvastatin, rosuvastatin, fluvastatin, lovastatin, and pitavastatin) inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. The reduction in cholesterol synthesis triggers a compensatory increase in LDL receptor expression to restore cholesterol levels. This increased expression of LDL receptors can lead to enhanced clearance of LDL cholesterol, which may indirectly reduce the functional activity of LDLRAD3, as it is involved in LDL regulation.

Other compounds, such as alirocumab and evolocumab, function as PCSK9 inhibitors. PCSK9 naturally targets LDL receptors for lysosomal degradation. By inhibiting PCSK9, these compounds increase the recycling and surface expression of LDL receptors, thus enhancing LDL clearance from the bloodstream. This could indirectly inhibit LDLRAD3 by altering the interactions and availability of its ligands. Additionally, compounds like ezetimibe, which inhibit the intestinal absorption of cholesterol, lomitapide, which inhibits the production of lipoproteins, mipomersen, which decreases apolipoprotein B-100 synthesis, and bempedoic acid, which also reduces cholesterol synthesis, can all influence LDLRAD3 activity.